...mutation status of TGFBR2, RHOA, and PREX2 influenced the PFS of immunotherapy...TGFBR2 p.P525L, p.P129Afs*3, p.E269* mutations had been identified and the median PFS of patients with TGFBR2wt and TGFBR2mt were 5.0 months (95%CI, 2.5–7.4 months) and 1.6 months (95%CI, 1.4–1.8 months; p < 0.001), respectively.